Betamethasone Valerate: Effects in Dermatology

Betamethasone Valerate (brand names Betnesol V, Betatop, Cordes Beta, and generics) is a topical glucocorticoid with moderate to high potency, classified as class III according to European standards. In Germany, betamethasone valerate is an established treatment for inflammatory skin diseases such as plaque psoriasis, atopic dermatitis, and contact dermatitis. It is available as a cream, ointment, lotion, and in some combination preparations with antibiotics or antifungals.

The class of topical glucocorticoids belongs to the most frequently prescribed substances in dermatological practice. Betamethasone valerate ranks in potency between weak hydrocortisone preparations and very strong substances such as clobetasol. Patients prescribed this medication benefit from rapid reduction of itching, redness, and scaling. At the same time, limited duration of use is important because continuous application can lead to skin atrophy and other local side effects.

Mechanism of Action

Betamethasone valerate binds to the intracellular glucocorticoid receptor in keratinocytes and inflammatory cells of the skin. The activated receptor migrates into the cell nucleus and affects gene expression, inhibiting pro-inflammatory mediators such as cytokines, chemokines, prostaglandins, and leukotrienes while inducing anti-inflammatory proteins such as annexin 1. Clinically, this results in reduction of inflammatory skin erythema, itching, scaling, and swelling.

Esterification with valeric acid improves lipid solubility and thus penetration into the stratum corneum. The active ingredient is moderately to highly potent (class III), stronger than hydrocortisone or prednicarbate but weaker than mometasone or clobetasol. This potency makes betamethasone valerate particularly suitable for moderately severe inflammatory skin diseases or thicker plaques on the trunk and extremities.

Systemic absorption through intact skin is low. With large-scale application, occlusive dressing, thin or inflamed skin, absorption can increase significantly. In infants and young children, skin surface area is larger in relation to body weight, which favors systemic effects.

Indications

• Plaque psoriasis, especially on the trunk and extremities
• Atopic dermatitis (eczema) during flares
• Allergic and toxic contact dermatitis
• Lichen simplex chronicus and lichen planus
• Discoid lupus erythematosus with dermatological support
• Seborrheic dermatitis with significant inflammatory component
• Combination preparations with antifungals or antibiotics for inflammatory skin diseases with secondary infection

Betamethasone valerate is not first-line for facial use, intertriginous areas (armpits, groin, genital region), and large skin surfaces because absorption is higher and atrophy risk is greater in these locations. Application is contraindicated in viral or bacterial skin infections without an inflammatory component.

Dosage and Application

Adults and children aged 12 years and older: Apply 0.1 percent cream or ointment thinly to affected areas once or twice daily. Treatment duration is typically maximum two to four weeks without dermatological re-evaluation.

Children between 1 and 12 years of age: Once daily on a small area, short-term, lower potency if possible. Use very restrictively on the face and intertriginous areas.

Infants under 12 months: Use only in exceptional cases because absorption is high.

Ointment versus cream: Ointment for dry and scaling skin areas, cream for moist or acutely inflamed areas. Lotion is suitable for the scalp.

Application technique: Apply a thin layer, gently massage in if necessary, do not use occlusive dressing (except on medical advice). Wash hands after application and protect eyes from contact.

Renal insufficiency and hepatic insufficiency: For topical application, dose adjustment is usually not necessary. For large-scale therapy, individual assessment is required.

Step-down reduction: After the acute phase subsides, switch to weaker steroids or reduce to intermittent use (twice weekly), supplemented by daily basic care with emollients.

Side Effects

Common: Burning or itching at the application site, dryness, especially in the first few days.

With longer or improper use: Skin atrophy with skin thinning, telangiectasia, striae distensae, pigment changes, acne, folliculitis, impaired wound healing, perioral dermatitis on the face.

Rare: Contact allergy to the active ingredient or excipients, secondary bacterial, viral, or fungal infections, steroid rosacea when applied to the face.

Systemic effects are rare with small-area application but occur with very large-scale application, occlusion, or in children, including Cushing syndrome, hyperglycemia, suppression of the hypothalamic-pituitary-adrenal axis, and growth retardation in children.

Rebound phenomenon: After abrupt discontinuation, especially after prolonged use, the disease may worsen. A step-down reduction and transition to weaker steroids or calcineurin inhibitors is advisable.

Drug Interactions

• Other topical glucocorticoids: combination is not necessary, additive effect is not beneficial.
• Topical calcineurin inhibitors (tacrolimus, pimecrolimus): useful combination in a step-down approach, especially on the face and in intertriginous areas.
• Calcipotriol: established combination for plaque psoriasis, often in fixed-combination preparations.
• UV therapy: combined use is possible, individual coordination required.
• Local antiseptics and antibiotics: specifically used in combination preparations.
• Live vaccines: caution with systemic absorption through large application areas, usually unproblematic with standard use.

Special Notes

Pregnancy: Application to small skin areas and short-term use is generally acceptable. Large-scale or prolonged use should be avoided because systemic absorption may affect birth weight. Breastfeeding: Do not apply directly to the breast and avoid application before breastfeeding because the infant could absorb the active ingredient.

Children: Use the lowest effective potency, smallest area, and short-term duration whenever possible. Use very restrictively on the face and in intertriginous areas. Monitor growth during long-term therapy.

Before starting therapy: Confirm skin diagnosis (exclude fungi, bacteria, viruses), define application area, and counsel on limited duration of use and rebound risk.

Supportive measures: Basic care with emollients (multiple times daily), trigger avoidance, stress management in atopic dermatitis. Patients often receive written step-down therapy guidance for acute phases and stable phases.

When to see a dermatologist: If no improvement after two weeks, worsening symptoms, secondary infection (increasing redness, pus, fever), skin atrophy, or suspected contact allergy.

Lifestyle: In psoriasis and atopic dermatitis, gentle skincare, avoidance of irritants, sun protection, and stress management are part of treatment success.

You might also be interested in

• Triamcinolone Acetonide, another moderately potent glucocorticoid
• Dexamethasone, highly potent systemic steroid
• Methylprednisolone, intermediate potency steroid
• Dexpanthenol, skin regenerating care
• Dithranol, classical antipsoriatic

Frequently Asked Questions

Sources

• Gelbe Liste, Betamethasone Active Ingredient Profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines for Psoriasis and Atopic Dermatitis
• German Dermatological Society